Regulators Say New Melanoma Drug is ‘Breakthrough’

Wednesday, 24 Apr 2013 04:50 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. regulators have granted Merck & Co.'s experimental treatment for advanced melanoma a "breakthrough therapy" designation, which could speed development and regulatory review of the product.
 
The medicine, whose chemical name is lambrolizumab, is also being tested against other forms of cancer. It belongs to a promising class of therapies that harness the body's immune system to find and attack cancer cells. It targets a protein called PD-1, or Programmed Death receptor.
 
The FDA created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
 
Although it is intended to provide an easier path for drug development, Merck said it was not yet clear what specific benefits the designation would afford.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved